Ultragenyx Pharmaceutical Inc.
RARE
$15.29
+2.69%
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for serious, rare, and ultra-rare genetic diseases, with a commercial portfolio that includes Crysvita for X-linked hypophosphatemia, Dojolvi for long-chain fatty acid oxidation disorders, and Mepsevii for Mucopolysaccharidosis VII. The company occupies a specialized niche in the rare-disease space, where its distinctiveness lies in a multi-product commercial platform combined with a deep gene-therapy pipeline, positioning it as a mid-cap player with both marketed revenue and high-risk, high-reward clinical optionality. The current investor narrative is dominated by a severe negative inflection: despite roughly 25.6% year-over-year revenue growth in the most recent quarter, the stock has collapsed approximately 44.7% in the past month and 50.2% over the past year, with a particularly violent single-day drop from $26.53 to $14.85 on September 3, 2026, suggesting a major clinical, regulatory, or competitive setback. This drawdown has turned the debate sharply toward pipeline risk, cash burn sustainability, and whether the commercial franchise alone can support the current enterprise value, even as 19 analysts maintain a consensus buy rating with an average target of $27.00.…
RARE
Ultragenyx Pharmaceutical Inc.
$15.29
Related headlines
Investment Opinion: Should I buy RARE Today?
The synthesized recommendation is Hold, with a clear thesis that the commercial franchise is undervalued but the pipeline risk and cash burn create too much uncertainty to justify a Buy at this time. The analyst consensus rating of buy and average target of $27.00 imply significant upside, but these are stale and do not reflect the September 2026 crash. The stock's 86% implied upside is tempting, but the lack of clarity on the cause of the crash and the company's reliance on external financing warrant caution.
Supporting evidence for a Hold includes the 25.55% year-over-year revenue growth in Q4 2025, the robust gross margin of 85.99%, and the historically low PS ratio of 3.37x. However, the TTM net margin of -85.4%, free cash flow of -$472 million, and negative shareholders' equity offset these positives. The forward PE of 71.90x and estimated EPS of $2.72 are not credible given the current quarterly loss of -$1.29 per share, and the PEG ratio of 0.54 is based on unreliable estimates. The stock is trading at a deep discount to its historical PS range, but the market is clearly pricing in a permanent impairment of the growth story.
The biggest risks that could invalidate the thesis are a further deterioration in cash position, a breakdown below the 52-week low of $12.73, and a wave of analyst downgrades. This Hold would upgrade to Buy if the company provides clarity on the September 3 crash and demonstrates a credible path to profitability, or if the stock stabilizes above $16.00 with improving fundamentals. It would downgrade to Sell if free cash flow burn accelerates or if the stock breaks below $12.73. Relative to its history and peers, the stock appears undervalued on a sales basis, but the negative FCF and reliance on financing mean the multiple is not directly comparable to cash-generative peers.
Sign up to view all
RARE 12-Month Price Forecast
The forward-looking view is neutral with medium confidence, as the company's robust revenue growth and deep value on sales are offset by persistent losses, negative shareholders' equity, and a lack of clarity on the September 2026 crash. The analyst consensus is bullish but stale, and the wide target range of $16.00 to $40.00 signals high uncertainty. The stock is likely to remain volatile, with the base case suggesting a trading range of $16.00 to $27.00 over the next 12 months. I would upgrade to bullish if the company provides a credible path to profitability and clarifies the cause of the crash, or downgrade to bearish if free cash flow burn accelerates or the stock breaks below $12.73.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Ultragenyx Pharmaceutical Inc.'s 12-month outlook, with a consensus price target around $26.79 and implied upside of +75.2% versus the current price.
Average Target
$26.79
0 analysts
Implied Upside
+75.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$16 - $39
Analyst target range
The stock is covered by 19 analysts, with a consensus recommendation of "buy" and a recommendation mean of 2.0 on a scale where 1 is strong buy and 5 is strong sell, indicating a moderately bullish stance. The average target price is $27.00, which implies approximately 86% upside from the current price of $14.51, a strikingly large gap that suggests either significant undervaluation or stale analyst estimates that have not yet been revised following the September 3 crash. The consensus estimated EPS average of $2.72 and estimated revenue average of $1.52 billion for the forward period imply a dramatic turnaround from the current quarterly loss of -$1.29 per share and TTM revenue run-rate of roughly $672 million, and the credibility of these estimates is now the key swing factor for the stock. The target range spans from a low of $16.00 to a high of $40.00, a 2.5x spread that signals very high uncertainty and divergent views on the company's pipeline and commercial trajectory. The high target of $40.00 likely assumes successful pipeline readouts, continued 25%+ revenue growth, and a path to profitability that justifies a premium multiple, while the low target of $16.00, which is only about 10% above the current price, prices in persistent losses, competitive pressure, and the possibility that the recent crash reflects a fundamental impairment rather than a sentiment-driven selloff. Institutional ratings data shows a cluster of Overweight and Buy ratings from firms including Cantor Fitzgerald, TD Cowen, RBC Capital, Barclays, and Wells Fargo, but all of these ratings predate the September 2026 crash, meaning they are likely stale and do not reflect the new information that drove the 44% single-day decline. The wide target spread and the staleness of the ratings suggest that the consensus is in a state of flux, and investors should expect a wave of downgrades and target cuts in the coming weeks as analysts incorporate the new reality.
Bulls vs Bears: RARE Investment Factors
The bear case currently has stronger evidence due to the recent 44% single-day crash, persistent deep losses, and negative shareholders' equity, which collectively signal a fundamental impairment rather than a sentiment-driven selloff. The bull case rests on robust revenue growth, a historically low PS ratio, and analyst targets that imply 86% upside, but these are undermined by stale ratings and a cash burn that requires continuous external financing. The single most important tension is whether the September 3 crash reflects a temporary setback or a permanent impairment of the pipeline; if it is the former, the stock is deeply undervalued, but if it is the latter, the commercial franchise alone may not support the current enterprise value. The market is clearly in price-discovery mode to the downside, and the stock's proximity to its 52-week low of $12.73 suggests that further downside is possible before a bottom is found. Until there is clarity on the cause of the crash and a credible path to profitability, the risk/reward remains skewed to the downside.
Bullish
- Revenue growth remains robust: Q4 2025 revenue reached $207 million, up 25.55% year-over-year, and the quarterly progression from $139.3 million in Q1 2025 to $207 million shows consistent sequential expansion. This growth is driven by a balanced mix of product sales ($101.7 million) and royalty revenue ($105.6 million), reducing reliance on any single commercial asset.
- Deep undervaluation on sales: The stock trades at a PS ratio of 3.37x, a fraction of its historical average and a 95% decline from its peak PS of 76.87x in Q1 2021. For a rare-disease company with 25%+ revenue growth and 86% gross margins, this multiple implies deep value if the commercial franchise is sustainable.
- Analyst consensus sees massive upside: 19 analysts maintain a consensus buy rating with an average target of $27.00, implying 86% upside from the current price of $14.51. The low target of $16.00 still represents 10% upside, suggesting that even the most cautious analyst sees limited downside from here.
- Strong gross margins and liquidity: Gross margin stands at 85.99% in Q4 2025, typical for a successful rare-disease franchise, and the current ratio of 2.48 indicates adequate short-term liquidity. Cash at the end of Q4 2025 was $436 million, up from $214.7 million in Q3 2025, providing a runway to fund operations.
Bearish
- Catastrophic price collapse: The stock has fallen 44.7% in the past month and 50.2% over the past year, with a single-day drop from $26.53 to $14.85 on September 3, 2026. This 44% gap-down represents a structural repricing event, likely tied to a binary clinical or regulatory setback, and the subsequent drift to $14.51 shows no stabilization.
- Persistent deep losses and cash burn: Q4 2025 net income was -$129 million on $207 million of revenue, a net margin of -62.3%, and TTM net margin is -85.4%. Free cash flow TTM is -$472 million, and the company relies on external financing, as evidenced by a $394.2 million net financing inflow in Q4 2025.
- Negative shareholders' equity: The debt-to-equity ratio of -15.95 reflects negative shareholders' equity, a red flag that complicates traditional leverage analysis. The PB ratio of -28.35 is similarly non-informative, and the company's balance sheet health is questionable despite the current ratio of 2.48.
- Stale analyst ratings and targets: All 19 analyst ratings and the $27.00 average target predate the September 2026 crash, meaning they are likely stale and do not reflect the new information that drove the 44% single-day decline. Investors should expect a wave of downgrades and target cuts in the coming weeks.
RARE Technical Analysis
RARE is in a severe, sustained downtrend, with the current price of $14.51 sitting just 4.5% above its 52-week low of $12.73 and a staggering 63.6% below its 52-week high of $39.89, placing it in the bottom 4.5% of its 52-week range. The 1-year price change of -50.15% and 6-month change of -26.98% confirm that this is not a short-term dip but a protracted decline, and the -64.75% maximum drawdown underscores the depth of the capital destruction. Trading this close to the 52-week low signals that the market is in price-discovery mode to the downside, where value buyers face the risk of a falling knife rather than a defined support bounce. Recent momentum is catastrophically negative and decelerating: the 1-month change of -44.70% and 3-month change of -47.12% are both far worse than the 1-year change of -50.15%, indicating that the bulk of the decline has occurred in just the last quarter. The single-session collapse from $26.53 on September 2 to $14.85 on September 3, 2026, a roughly 44% gap-down, represents a structural repricing event, likely tied to a binary clinical or regulatory catalyst, and the subsequent drift to $14.51 shows no meaningful stabilization. Relative strength versus SPY is deeply negative across every window, with -43.74% over 1 month and -65.16% over 1 year, confirming that this is idiosyncratic weakness rather than broad market pressure. Key technical levels are now defined by the 52-week low at $12.73, which serves as the last line of support; a breakdown below that level would open the door to new all-time-low territory and likely trigger further momentum-driven selling. Resistance is layered, with the post-gap consolidation zone around $15.30-$16.00 as immediate overhead, followed by the pre-gap level near $26.53, which now represents a massive 83% recovery hurdle. Notably, the beta of 0.315 suggests the stock is only about 32% as volatile as the broader market on a historical basis, but the recent gap-down and 8.15 short ratio indicate that event risk and crowded short positioning, not beta, are the dominant risk factors for position sizing.
Beta
0.35
0.35x market volatility
Max Drawdown
-64.8%
Largest decline past year
52-Week Range
$13-$40
Price range past year
Annual Return
-50.5%
Cumulative gain past year
| Period | RARE Return | S&P 500 |
|---|---|---|
| 1m | +2.8% | +1.0% |
| 3m | -54.8% | +2.5% |
| 6m | -34.4% | +13.9% |
| 1y | -50.5% | +15.0% |
| ytd | -35.2% | +13.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RARE Fundamental Analysis
Ultragenyx's revenue trajectory remains a bright spot within an otherwise deteriorating equity story: Q4 2025 revenue reached $207 million, representing 25.55% year-over-year growth, and the quarterly progression from $139.3 million in Q1 2025 to $207 million in Q4 2025 shows consistent sequential expansion. Revenue is split between product sales of $101.7 million and royalty revenue of $105.6 million, a balanced mix that reduces reliance on any single commercial asset, though the royalty stream is likely tied to partner-driven Crysvita sales and therefore carries counterparty and geographic concentration risk. The multi-quarter trend from Q1 2024's $108.8 million to Q4 2025's $207 million represents roughly 90% cumulative growth over eight quarters, which is impressive for a rare-disease commercial-stage company, but the market is clearly discounting this growth in favor of pipeline and cash-flow concerns. Profitability remains deeply negative: Q4 2025 net income was -$129 million on $207 million of revenue, a net margin of -62.3%, and the TTM net margin is -85.4%, with operating margin at -79.5%. Gross margin is robust at 85.99% in Q4 2025 and 83.8% on a TTM basis, which is typical for a successful rare-disease therapeutic franchise, but the company's heavy R&D spend of $203 million in Q4 2025 alone, plus $89 million in SG&A, overwhelms the gross profit of $178 million. The loss trajectory is not improving: Q4 2025's -$129 million net loss compares unfavorably to Q4 2024's -$133.4 million, and the Q3 2025 loss of -$180.4 million was the widest in the trailing eight quarters, indicating that operating leverage has not yet materialized despite revenue growth. The balance sheet presents a mixed picture: the current ratio of 2.48 and quick ratio of 2.34 suggest adequate short-term liquidity, but free cash flow TTM is -$472 million, and the debt-to-equity ratio of -15.95 reflects negative shareholders' equity, a red flag that complicates traditional leverage analysis. Cash at the end of Q4 2025 was $436 million, up from $214.7 million in Q3 2025 due to a $394.2 million net financing inflow, which included $392 million of debt repayment activity and $219.2 million of common stock issuance, indicating the company is reliant on external capital markets to fund its cash burn. The cash flow coverage ratio of -0.078 and operating cash flow of -$99.8 million in Q4 2025 confirm that internal cash generation is insufficient to fund operations, and with a -$100.8 million free cash flow in the quarter, the company's runway depends on continued access to financing, a significant risk in a risk-off biotech tape.
Quarterly Revenue
$214000000.0B
2026-06
Revenue YoY Growth
+28.5%
YoY Comparison
Gross Margin
84.1%
Latest Quarter
Free Cash Flow
$-489468000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RARE Overvalued?
Because Ultragenyx reported negative net income of -$129 million in Q4 2025 and a trailing PE of -3.95, the PE ratio is not meaningful; the appropriate primary metric is the price-to-sales ratio, which stands at 3.37x on a trailing basis and 3.27x on an EV-to-sales basis. The forward PE of 71.90x is positive, implying the market expects a dramatic swing to profitability, with consensus estimated EPS of $2.72 for the forward period, a forecast that stands in stark contrast to the current quarterly loss of -$1.29 per share. This enormous gap between trailing losses and forward profitability expectations suggests the market is pricing in either a major pipeline catalyst, a substantial revenue inflection, or aggressive cost restructuring, and the credibility of that forecast is now the central valuation question. On a peer-relative basis, the PS ratio of 3.37x is difficult to benchmark without explicit industry average data, but for context, the company's own historical PS ratio has ranged from a high of 76.87x in Q1 2021 to a low of 11.1x in Q4 2025, and the current 3.37x is a fraction of even the most recent historical reading. The EV-to-EBITDA of -6.56x is negative and therefore not comparable to profitable peers, while the PB ratio of -28.35 reflects negative book value and is similarly non-informative. The PEG ratio of 0.54 is the one metric that screens as potentially attractive, but it is derived from a forward EPS estimate that may not be reliable given the company's persistent losses. Historically, RARE's PS ratio has compressed dramatically from the 60x-77x range in 2021 to the 11x-25x range in 2024-2025, and now to 3.37x, a decline of over 95% from peak levels. This compression reflects both the stock price collapse and the revenue growth that has occurred, but it also raises the question of whether the market is now pricing in a permanent impairment of the growth story or simply a temporary dislocation. At 3.37x sales, the stock is trading at a level that would be considered deep value for a profitable rare-disease company, but the negative FCF and reliance on external financing mean the multiple is not directly comparable to cash-generative peers.
PE
-3.9x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-6.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are severe: the company reported a Q4 2025 net loss of -$129 million on $207 million of revenue, a -62.3% net margin, and TTM free cash flow of -$472 million. With cash of $436 million at year-end 2025 and a quarterly cash burn of approximately $100 million, the runway is limited to roughly four quarters without additional financing. The debt-to-equity ratio of -15.95 indicates negative shareholders' equity, and the company's reliance on external capital markets is evident from the $394.2 million net financing inflow in Q4 2025, which included $219.2 million of common stock issuance. This dependence on financing exposes the company to risk-off biotech market conditions and potential dilution for existing shareholders.
Market and competitive risks are amplified by the recent 44% single-day crash, which suggests a binary clinical or regulatory setback that has yet to be fully understood. The stock's beta of 0.315 is low, but the recent gap-down and short ratio of 8.15 indicate that event risk and crowded short positioning are the dominant risk factors. The wide analyst target range of $16.00 to $40.00 signals very high uncertainty, and the consensus buy rating is likely stale, with downgrades expected. Competitive pressures in the rare-disease space are intense, and any loss of market share for Crysvita or pipeline failures could further erode investor confidence.
In a worst-case scenario, the stock could break below its 52-week low of $12.73, opening the door to new all-time lows and triggering further momentum-driven selling. From the current price of $14.51, a decline to the 52-week low represents a 12.3% loss, but if the company's pipeline setbacks prove fundamental, the stock could fall to the analyst low target of $16.00 (which is above current price) or lower, potentially to single digits. The maximum drawdown of -64.75% from the 52-week high of $39.89 illustrates the depth of capital destruction possible, and investors could lose an additional 30-50% from current levels if the bear case materializes.
FAQ
The most severe risk is financial: the company burned $472 million in free cash flow over the trailing twelve months and has negative shareholders' equity, with a debt-to-equity ratio of -15.95. This necessitates continuous external financing, which could lead to dilution. Second, pipeline risk is high, as the September 3 crash likely reflects a clinical or regulatory setback, and any further failures could devastate the stock. Third, competitive risk in the rare-disease space is intense, and Crysvita, which drives a significant portion of revenue, faces potential competition. Fourth, macro risk includes the possibility of a risk-off biotech tape, which would make it harder for the company to raise capital and could compress valuations further. The short ratio of 8.15 also indicates crowded short positioning, which could amplify downside moves.
The 12-month forecast is divided into three scenarios: a bull case with 20% probability targeting $27-$40, a base case with 50% probability targeting $16-$27, and a bear case with 30% probability targeting $12.73-$16. The base case is most likely, assuming revenue growth moderates to 15-20% and the company stabilizes without major pipeline news. The key assumption is that the September 2026 crash was an overreaction and that the commercial franchise can support the enterprise value. However, if the crash reflects a fundamental impairment, the bear case could materialize, pushing the stock below its 52-week low. The wide analyst target range of $16.00 to $40.00 reflects the high uncertainty.
RARE appears undervalued on a price-to-sales basis, trading at 3.37x trailing sales compared to its historical average of over 20x and a peak of 76.87x in Q1 2021. However, the negative net margin of -85.4% and free cash flow of -$472 million mean the multiple is not directly comparable to profitable peers. The forward PE of 71.90x implies the market expects a dramatic swing to profitability, with consensus EPS of $2.72, which contrasts sharply with the current quarterly loss of -$1.29 per share. The market is pricing in either a major pipeline catalyst or aggressive cost restructuring, and the credibility of that forecast is the central valuation question. If the company fails to deliver on these expectations, the stock could be overvalued even at 3.37x sales.
RARE is not a good buy for most investors at current levels due to the high uncertainty surrounding the September 2026 crash and the company's persistent cash burn. The stock trades at $14.51, with a consensus target of $27.00 implying 86% upside, but these targets are stale and do not reflect the recent 44% single-day decline. The biggest downside risk is a break below the 52-week low of $12.73, which could lead to further losses. For risk-tolerant investors with a long-term horizon, a small position could be justified if the company provides clarity on the crash and a credible path to profitability. However, the negative free cash flow of -$472 million and reliance on external financing make it a speculative bet.
RARE is more suitable for long-term investment by risk-tolerant investors, as the company is in a growth stage with a deep pipeline and commercial products, but it does not pay a dividend and has high earnings volatility. The beta of 0.315 suggests lower market correlation, but the recent 44% single-day drop shows that idiosyncratic event risk is significant. Short-term trading is highly risky due to the potential for further volatility and the lack of clear support levels. A minimum holding period of 2-3 years is recommended to allow for pipeline readouts and a potential path to profitability. Investors should be prepared for dilution and further drawdowns before any recovery.